Traws Pharma (TRAW) News Today $1.42 0.00 (0.00%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.40 -0.01 (-1.06%) As of 06:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Traws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | finanznachrichten.deTraws Pharma receives approval to proceed with Phase 2 COVID studiesAugust 18, 2025 | msn.comTraws Pharma Gains Approval for Phase 2 COVID-19 TrialsAugust 18, 2025 | msn.comTraws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | globenewswire.comTraws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral ProgramsAugust 16, 2025 | msn.comTraws Pharma Advances Antiviral Programs Amid Revenue GrowthAugust 16, 2025 | theglobeandmail.comTraws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comTraws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | finanznachrichten.deTraws Pharma Stock Short Interest Report | NASDAQ:TRAW - BenzingaAugust 14, 2025 | benzinga.comTraws Pharma reports Q2 EPS (11c) vs. ($20.52) last yearAugust 14, 2025 | msn.comTraws Pharma Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comTraws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | finance.yahoo.comTraws Pharma, Inc. (TRAW) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTraws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | globenewswire.comTraws Pharma to Announce Q2 Results and Business Update on August 14August 10, 2025 | msn.comTraws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025August 8, 2025 | globenewswire.comTRAW - Traws Pharma Inc Sustainability - MorningstarJuly 16, 2025 | morningstar.comMCooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws PharmaJuly 8, 2025 | msn.comTraws Pharma announces chief financial officer transitionJuly 5, 2025 | uk.investing.comTraws Pharma, Inc. (TRAW) Income Statement - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTraws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | finanznachrichten.deTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsJune 30, 2025 | globenewswire.comTraws Pharma Announces Promising Clinical Data for Rigosertib in Rare CancerJune 5, 2025 | msn.comTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibJune 3, 2025 | globenewswire.comTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessMay 27, 2025 | globenewswire.comTraws Pharma Unveils New Strategic Antiviral FocusMay 19, 2025 | tipranks.comTraws Pharma Highlights Q1 2025 Financial Progress and Antiviral DevelopmentsMay 18, 2025 | msn.comTraws Pharma Reports First Quarter 2025 Results and Business HighlightsMay 15, 2025 | globenewswire.comTraws Pharma Appoints New Chairman Amid Leadership ChangesApril 18, 2025 | tipranks.comTraws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID ProgramsApril 2, 2025 | msn.comTraws Pharma reports FY24 EPS ($35.21)April 1, 2025 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Virtual Investor Event TranscriptApril 1, 2025 | seekingalpha.comTraws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | finanznachrichten.deTraws Pharma Reports Full Year 2024 Results and Business HighlightsMarch 31, 2025 | markets.businessinsider.comTraws Pharma Announces CEO Transition as Werner Cautreels RetiresMarch 30, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Announces Management UpdatesMarch 29, 2025 | finanznachrichten.deTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAWMarch 29, 2025 | marketwatch.comTraws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19March 29, 2025 | msn.comTraws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEOMarch 29, 2025 | markets.businessinsider.comTraws Pharma Announces Management UpdatesMarch 28, 2025 | globenewswire.comTraws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 TreatmentMarch 27, 2025 | msn.comTraws Pharma Reports Promising Preclinical Results for Bird Flu TreatmentMarch 27, 2025 | msn.comTraws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ETMarch 26, 2025 | globenewswire.comTraws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICARMarch 25, 2025 | markets.businessinsider.comTraws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICARMarch 25, 2025 | globenewswire.comTraws Pharma announces results from study of tivoxavir marboxil in bird fluMarch 24, 2025 | markets.businessinsider.comTraws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human PrimatesMarch 24, 2025 | markets.businessinsider.comTraws Pharma Unveils Promising Bird Flu Treatment DataMarch 22, 2025 | msn.comTraws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICARMarch 21, 2025 | markets.businessinsider.com Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Media Mentions By Week TRAW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRAW News Sentiment▼1.871.03▲Average Medical News Sentiment TRAW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRAW Articles This Week▼12▲TRAW Articles Average Week Get the Latest News and Ratings for TRAW and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Traws Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies LAVA Therapeutics News Today Renovaro News Today CalciMedica News Today Medicus Pharma News Today Mersana Therapeutics News Today OnKure Therapeutics News Today Exicure News Today ESSA Pharma News Today Xilio Therapeutics News Today Estrella Immunopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRAW) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access